Karolinska Development's portfolio company Umecrine Cognition to collaborate with University College London to increase insights about golexanolone
19 October 2021 - 3:56PM
Karolinska Development's portfolio company Umecrine Cognition to
collaborate with University College London to increase insights
about golexanolone
STOCKHOLM, SWEDEN – October 19, 2021. Karolinska Development AB
(Nasdaq Stockholm: KDEV) announces today that the portfolio company
Umecrine Cognition has entered a collaboration with Professor
Trevor G Smart and his research group at University College London.
The collaboration will involve molecular analysis and behavioral
studies of Umecrine Cognition's most advanced drug candidate,
golexanolone.
Umecrine Cognition's drug candidate golexanolone is currently in
Phase 2 clinical development as a new treatment for hepatic
encephalitis (liver coma). The compound represents an innovative
class of drugs that interact with the GABAA receptor in order to
balance central nervous system activity and thereby counteract
severe disease symptoms. The collaboration with Professor Smart's
research group represents a strategic step in the development of
golexanolone.
Using state-of-the-art research techniques in structural
biology, synaptic physiology and established behavioural models,
Professor Smart and his group study the effects of neurosteroids on
the GABAA receptor and how these interactions influence behaviour.
The collaboration will include studies to evaluate the interaction
of golexanolone and other neurosteroids with the target receptor,
and how such interactions affect neuronal signalling with relevance
to medical treatment of certain diseases.
“Umecrine Cognition's newly established collaboration with the
internationally renowned research group at University College
London has the potential to generate further valuable knowledge to
support the continued development of both golexanolone and the
company's next generation of drug candidates,” says Viktor Drvota,
CEO, Karolinska Development AB in a comment.
Karolinska Development's ownership interest in Umecrine
Cognition amounts to 70%.
For further information, please
contact:
Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982
52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development ABPhone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development ABKarolinska
Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough
medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the
creation and growth of companies that advance these assets into
commercial products that are designed to make a difference to
patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
- PM KD UC UCL-samarbete ENG
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Apr 2023 to Apr 2024